Differentiation of Human Embryonic Stem Cells to Insulin Producing Cell Clusters Anish S. Majumdar, Ph.D. Senior Director, Immunology, Geron Corporation, Menlo Park, CA
"Recent success in cadaveric islet transplantation for patients with type I diabetes has increased interest in discovering an alternative source of stem cells with potential to differentiate into pancreatic ? cells. Human embryonic stem cells (hESCs), which are immortal and capable of both self-renewal and differentiation, could be used for this purpose. We have developed a three-stage differentiation protocol in which human embryonic stem cells (hESCs) are allowed to differentiate to definitive endoderm. In the presence of selective growth factors, extracellular matrix and maturation inducing factors, the pancreatic component of the endoderm differentiates into insulin and glucagon expressing islet-like cell clusters. These clusters, similar to human islets, secrete C-peptide in response to glucose challenge. In vitro and in vivo properties of these islet-like cells derived from hESCs will be discussed at the meeting."
It means they are looking to inprome teh yeild of islet � cells from hESCs - its alerady consider a treatment, the issue has been making enough of it
We have derived insulin-producing islet � cells (i.e. similar to pancreatic islet � cells) from hESCs and are working to improve the yield of islet cells and characterize their secretion of insulin in response to glucose. We have begun transplanting the islets to animal models of diabetes and early results show prolonged survival of engrafted animals and the detection of human insulin in their blood.
Geron makes pancreatic islet cells that produce insulin in a dose dependent fashion based on the amount of glucose that they are exposed to. They are working on increasing the efficiency of production.